Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.
We currently have 28 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.9 billion (IQVIA, February 2018).
We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.
"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."
Damian Finio
CFO
Recent News
Teligent, Inc. Announces FDA Approval of Fluocinonide Gel, 0.05%
BUENA, N.J. , June 20, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...
( FY 2018 )
